Newsroom | 58300 results

MIAMI--(BUSINESS WIRE)--O.N.E Amazon calls for biodiversity to be treated as critical global infrastructure at the Nobel Sustainability Trust Summit 2025...

LOS ANGELES--(BUSINESS WIRE)--Researchers from City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation’s top cancer centers by U.S. News & World Report, presented scientific results on novel therapies, treatment strategies, and approaches to managing side effects and complications for blood cancer patients at the 2025 American Society of Hematology (ASH) conference in Orland...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--SonoThera™, a biotechnology company dedicated to treating the root cause of human diseases by developing the next generation of genetic medicines, today announced it will present new data at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9th in Orlando, Florida. SonoThera’s oral presentation focuses on the safe delivery of DNA expression vectors to the liver in non-human primate (NHP) models using...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new data highlighting the potential of Lunsumio® (mosunetuzumab-axgb) in earlier treatment lines for people living with different types of lymphoma, presented at the 67th American Society of Hematology Annual Meeting and Exposition, December 6-9, 2025 in Orlando, Florida. “These data underscore the potential of Lunsumio to support more people living with lymphoma, b...

WILMINGTON, Del.--(BUSINESS WIRE)--Updated Positive Data at ASH 2025 Reinforce the Potential of Incyte's INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in ET...

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025...

ORLANDO, Fla.--(BUSINESS WIRE)--Qihan Biotech, a clinical-stage biotechnology company developing off-the-shelf cell therapies for autoimmune diseases and cancer, including allogeneic CAR-T and in vivo CAR-T therapies, presented an oral and several poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting. The data included encouraging clinical results with the company’s allogeneic CAR-T program and foundational preclinical work supporting its emerging in vivo CAR-T pr...

SYDNEY--(BUSINESS WIRE)--Box, Inc. (NYSE: BOX), the leading Intelligent Content Management (ICM) platform, today announced that the Heart Research Institute (HRI), a renowned medical research institute, selected Box to centralise and secure its research content. HRI will leverage Box to gain AI-power insights across content sources, seamlessly integrate into research applications, and maintain robust compliance features built for healthcare and scientific sectors. "We are thrilled to partner wi...

NATICK, Mass. & LONDON--(BUSINESS WIRE)--Aleta Biotherapeutics, a clinical stage immuno-oncology company developing CAR T-cell engager biologics that enable CAR T-cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, today announced promising results from the phase I/II clinical trial of ALETA-001 in patients who have received anti-CD19 CAR T-cell therapy for the treatment of B-cell malignancies. The multi-centre, open-label clinical trial (NCT060...

LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to improving the conduct of clinical trials, today announced the completion of enrollment of 550+ patients at 50+ sites for a single study in just six months, using it’s proprietary AnovaOS™ Platform. The program provided cancer doctors and patients with a promising treatment that was otherwise unavailable. The sponsor was provided with safety and efficacy data to support its drug development...